MYC and breast cancer: Increased cyclin E-CDK2 activity appears to be a principal mechanism contributing to MYC-induced G1-S phase transition in breast cancer cells[10,11], possibly through suppression of the CDK inhibitor p21[12,13] and induction of the CDK phosphatase CDC25A[14].